Sol-Gel Technologies (SLGL) Competitors $7.71 -0.09 (-1.15%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLGL vs. CLYM, SNTI, GALT, ADAG, PLRX, OCX, GNTA, CRVO, PYXS, and TELOShould you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Climb Bio (CLYM), Senti Biosciences (SNTI), Galectin Therapeutics (GALT), Adagene (ADAG), Pliant Therapeutics (PLRX), OncoCyte (OCX), Genenta Science (GNTA), CervoMed (CRVO), Pyxis Oncology (PYXS), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry. Sol-Gel Technologies vs. Climb Bio Senti Biosciences Galectin Therapeutics Adagene Pliant Therapeutics OncoCyte Genenta Science CervoMed Pyxis Oncology Telomir Pharmaceuticals Climb Bio (NASDAQ:CLYM) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, community ranking, analyst recommendations, media sentiment, profitability, risk and earnings. Does the media prefer CLYM or SLGL? In the previous week, Climb Bio had 7 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 7 mentions for Climb Bio and 0 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.00 beat Climb Bio's score of -0.42 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Overall Sentiment Climb Bio Neutral Sol-Gel Technologies Neutral Do analysts recommend CLYM or SLGL? Climb Bio presently has a consensus price target of $10.00, indicating a potential upside of 726.45%. Sol-Gel Technologies has a consensus price target of $40.00, indicating a potential upside of 412.82%. Given Climb Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Climb Bio is more favorable than Sol-Gel Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CLYM or SLGL? Sol-Gel Technologies received 147 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 63.40% of users gave Sol-Gel Technologies an outperform vote. CompanyUnderperformOutperformClimb BioOutperform Votes2100.00% Underperform VotesNo VotesSol-Gel TechnologiesOutperform Votes14963.40% Underperform Votes8636.60% Which has preferable valuation & earnings, CLYM or SLGL? Sol-Gel Technologies has higher revenue and earnings than Climb Bio. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$35.12M-$2.38-0.51Sol-Gel Technologies$11.54M1.88-$27.24M-$3.80-2.05 Is CLYM or SLGL more profitable? Climb Bio has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -81.75%. Sol-Gel Technologies' return on equity of -27.17% beat Climb Bio's return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -42.21% -41.39% Sol-Gel Technologies -81.75%-27.17%-22.49% Which has more risk and volatility, CLYM or SLGL? Climb Bio has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Do institutionals and insiders hold more shares of CLYM or SLGL? 69.8% of Climb Bio shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 0.8% of Climb Bio shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryClimb Bio beats Sol-Gel Technologies on 9 of the 17 factors compared between the two stocks. Get Sol-Gel Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLGL vs. The Competition Export to ExcelMetricSol-Gel TechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.73M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-22.948.9226.8419.71Price / Sales1.88250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book4.676.466.794.50Net Income-$27.24M$143.98M$3.23B$248.18M7 Day Performance-0.13%3.04%4.07%1.14%1 Month Performance33.33%7.44%12.52%15.20%1 Year Performance-2.46%-2.46%16.83%6.56% Sol-Gel Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLGLSol-Gel Technologies2.1765 of 5 stars$7.80flat$40.00+412.8%+10.6%$21.73M$11.54M-22.9450Gap UpCLYMClimb Bio2.5919 of 5 stars$1.27-1.6%$10.00+687.4%N/A$85.82MN/A-0.609News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpSNTISenti Biosciences1.696 of 5 stars$3.24+1.9%$12.00+270.4%-14.9%$84.50M$2.56M-0.214GALTGalectin Therapeutics1.2377 of 5 stars$1.33+3.9%$11.00+727.1%-59.2%$84.03MN/A-1.829Earnings ReportADAGAdagene2.319 of 5 stars$1.77flat$8.00+352.0%-40.0%$83.39M$103,204.000.00260PLRXPliant Therapeutics4.2448 of 5 stars$1.35-2.2%$13.31+886.1%-90.9%$82.87M$1.58M-0.4090Positive NewsOCXOncoCyte2.3645 of 5 stars$2.80+0.4%$4.42+57.7%+6.5%$80.08M$3.84M-0.79120Analyst ForecastGap DownGNTAGenenta Science1.5102 of 5 stars$4.37+2.9%$25.00+471.6%+43.4%$80MN/A0.007Gap DownCRVOCervoMed3.3215 of 5 stars$8.79+0.1%$27.63+214.3%-55.5%$76.50M$7.14M-4.034PYXSPyxis Oncology1.4147 of 5 stars$1.23+1.7%$9.00+631.7%-71.1%$76.20M$16.15M-1.1960News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpTELOTelomir Pharmaceuticals1.7562 of 5 stars$2.54+1.6%$15.00+490.6%-62.1%$75.60MN/A-4.381News CoverageGap Up Related Companies and Tools Related Companies Climb Bio Alternatives Senti Biosciences Alternatives Galectin Therapeutics Alternatives Adagene Alternatives Pliant Therapeutics Alternatives OncoCyte Alternatives Genenta Science Alternatives CervoMed Alternatives Pyxis Oncology Alternatives Telomir Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLGL) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sol-Gel Technologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sol-Gel Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLGL Stock Free SLGL Stock Alerts